Patients in lower income European countries face years of access delays to innovative medicines compared to those in richer countries. A major reason for such delays is limited affordability in these markets. Data evaluating prices of innovative medicines in Europe show no relationship with per capita income. In fact, in several cases, prices in lower income countries can be higher than in richer ones. This leads to delayed or limited reimbursement of medicines in the lower income countries. Where companies do lower price to account for affordability, this is done on an ad hoc basis, and the process to get internal alignment on such prices takes a long time adding to access delays. A structured framework that allows for pricing based on local affordability and other local health system factors can expedite both company process and payer reimbursement times. We evaluated different ways to arrive at differential prices such as based on income per capita (linear and non-linear formulas), healthcare spend per capita and medicine spend per capita. We also looked as local payer reimbursement processes and methodologies such as cost effectiveness analyses and thresholds. Based on this assessment, we realised that there is no one size fits all formula that would work for all medicines. Rather, we propose a five step algorithm that can be applied across medicines. These include (1) differentiating prices based on per capita GNI; and adjusting the results based on (2) local reimbursement requirements; (3) local disease priorities; (4) the alternative treatments available and (5) other strategic/policy considerations specific to the medicine. We believe that this algorithm can help companies determine and internally align on appropriate prices quickly as well as cut reimbursement negotiation delays by addressing payer requirements proactively at the first instance. Such an approach will help reduce access inequity in Europe.